Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China. Hutchison China MediTech (Chi-Med) has been granted approval in its home market for Elunate, the first drug discovered and developed in China ... alongside AZ’s EGFR inhibitor Iressa (gefitinib), as

Latest news

More from news
Approximately 4 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast / gastric cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics